Samuel C. Blackman - 26 May 2021 Form 3 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Medical Officer
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
26 May 2021
Net transactions value
$0
Form type
3
Filing time
26 May 2021, 21:00:28 UTC
Next filing
03 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DAWN Common Stock 2,386,718 26 May 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DAWN Stock Option (right to buy Common Stock) 26 May 2021 Common Stock 58,167 $16.00 Direct F2
holding DAWN Stock Option (right to buy Common Stock) 26 May 2021 Common Stock 134,900 $16.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
F2 The option vests as to 25% of the total shares on October 6, 2021 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on October 6, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3 The option vests as to 25% of the total shares on May 23, 2022 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on May 23, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.